You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
THE WRAP-IT STUDY: THE LARGEST RANDOMISED, CONTROLLED, GLOBAL CIED TRIAL1
INTERNATIONAL CONSENSUS DOCUMENT RECOMMENDS TYRX™ CARDIAC ENVELOPE TO REDUCE CIED INFECTION21
Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. N Engl J Med. 2019;380(20):1895-1905.
Tarakji KG, et al. Arrhythm Electrophysiol Rev. 2016;5:65-71.
Tarakji KG, et al. N Engl J Med. 2019;380:1895-1905.
Wilkoff BL. AHA Scientific Sessions 2019; Su3088.
Sohail MR, et al. Circ Arrhythm Electrophysiol. 2016;9:e003929.
Clémenty N et al. Europace. 2018;20(12):1974-1980
Ludwig S et al. J Comp Eff Res. 2018;7(5):483-492.
Ahsan SY et al. Europace. 2014; (16):1482–1489.
Burnhope E et al. J Med Econ. 2019 Feb 12:1-7 epub.
Ahsan SY, et al. Europace. 2014;16:1482-1489.
Egea M, et al. Poster Presentation EHRA Congress 2018.
Tarakji KG, Ellis CR, Defaye P. Kennergren C. Cardiac Implantable Electronic Device Infection in Patients at Risk, Arrhythm Electrophysiol Rev. May 2016; 5 (1): 65-71. Bloom HL, Constantin L, Dan D, et al.
Mittal S, Shaw RE, Michel K, et al. Cardiac implantable electronic device infections: incidence risk factors, and the effect of the AigisRx antibacterial envelope. Heart Rhythm. April 2014;11(4):595-601.
Kolek MJ, Patel NJ, Clair WK, et al. Efficacy of a Bio-Absorbable Antibacterial Envelope to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Subjects. J Cardiovasc Electrophysiol. October 2015;26(10):1111-1116.
Shariff N, Eby E, Adelstein E, et al. Health and Economic Outcomes Associated with Use of an Antimicrobial Envelope as a Standard of Care for Cardiac Implantable Electronic Device Implantation. J Cardiovasc Electrophysiol. July 2015;26(7):783-789.
Kolek MJ, Dresen WF, Wells QS, Ellis CR. Use of an antibacterial envelope is associated with reduced cardiac implantable electronic device infections in high-risk patients. Pacing Clin Electrophysiol. March 2013;36(3):354-361.
Huntingdon Life Sciences Study TR-2011-054.
Osoro M, et al. Pacing Clin Electrophysiol. 2018;41:136-142.
Ferrando JM, et al. World J Surg. 2001;25:840-847.
Henrikson CA, Sohail MR, Acosta H, et al. Antibacterial Envelope Is Associated With Low Infection Rates After Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Device Replacement: results of the Citadel and Centurion Studies. JACC Clin Electrophysiol. October 2017;3(10):1158-1167.
Blomstrom-Lundqvist C, et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device. Europace 2019;1–35.
The TYRX Absorbable Antibacterial Envelope is intended to hold a pacemaker pulse generator or defibrillator securely in order to provide a stable environment when implanted in the body.
The TYRX Absorbable Antibacterial Envelope contains the antimicrobial agents minocycline and rifampin, which have been shown to reduce infection in an in vivo model of bacterial challenge following surgical implantation of the generator or defibrillator. The TYRX Absorbable Antibacterial Envelope is NOT indicated for use in patients who have an allergy or history of allergies to tetracyclines, rifampin, or absorbable sutures.
The TYRX Absorbable Antibacterial Envelope is also NOT indicated for use in patients with contaminated or infected wounds, or Systemic Lupus Erythematosus (SLE). The use of this product in patients with compromised hepatic and renal function, or in the presence of hepatotoxic or renal toxic medications, should be considered carefully, because minocycline and rifampin can cause additional stress on the hepatic and renal systems.
Patients who receive the TYRX Absorbable Antibacterial Envelope and who are also taking methoxyflurane should be monitored carefully for signs of renal toxicity.